OMICS for Tumor Biomarker Research

Moshkovskii, Sergei A.; Pyatnitsky, Mikhail; Lokhov, Petr G.; Baranova, Ancha

doi:10.1007/978-94-007-7681-4_14

Cited by 5 publications

(3 citation statements)

References 91 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The first systemic development of “-omics” science in Russia started in the early 2000s at the Institute of Biomedical Chemistry (IBMC) in Moscow. By that time, IBMC, dealing with problems of biological and medical chemistry under the leadership of academician of the Russian Academy of Sciences (RAS) Alexsander I. Archakov, was actively developing post-genomic technologies, such as transcriptomics and proteomics [ 7 , 8 , 9 , 10 , 11 , 12 , 13 ]. In 2000, the first in the country Department of Proteomic Research and, in 2003, the “Human proteome” Core Facility was created at IBMC.…”

Section: Metabolomics In Russiamentioning

confidence: 99%

“…With continuous optimization and improvement of high-tech research methods, metabolomics has become a wide area for the use of “-omics” technologies for medical purposes, the results of which are promising for future implementation [ 12 , 68 , 69 ]. With the support of the National Cancer Institute (NCI), Food and Drug Administration (FDA), and others, the Institute of Medicine (IOM) has been called upon to define the criteria and procedures for assessing the validity of tests created for the clinic.…”

Section: Current Trends In Metabolomicsmentioning

confidence: 99%

See 1 more Smart Citation

Metabolomics Community in Russia: History of Development, Key Participants, and Results

Balashova

Maslov

Trifonova

2020

BioTech

View full text Add to dashboard Cite

Metabolomics is the latest trend in the “-omics” sciences, of which technologies are widely used today in all life sciences. Metabolomics gave impetus to the description of biochemical processes that occur in many organisms, search for new biomarkers of disease, and laid the foundation for new clinical laboratory diagnostics. The purpose of this review is to show how metabolomics is represented in Russian science, what main research areas were chosen, and to demonstrate the successes and main achievements of Russian scientists in this field. The review is dedicated to the 10th anniversary of Russian metabolomics and also touches on the history of the formation of Russian metabolomics and prospects for the future.

show abstract

Section: Metabolomics In Russiamentioning

confidence: 99%

Section: Current Trends In Metabolomicsmentioning

confidence: 99%

Metabolomics Community in Russia: History of Development, Key Participants, and Results

Balashova

Maslov

Trifonova

2020

BioTech

View full text Add to dashboard Cite

show abstract

“…A high dimensionality of the data in relation to small numbers of available samples (often referred to as the p >> n problem), influences of additive and multiplicative noise, large numbers of uninformative or redundant data features, outliers, confounding factors and imbalanced sample group numbers are all common characteristics of current biomedical data collections. While first successes have been achieved in developing clinical decision support tools using multifactorial omics data, e.g., resulting in FDA-approved omics-based biomarker signatures for common cancer indications [ 1 ], there is still an unmet need and great potential for earlier, more accurate and robust diagnostic and prognostic tools for many complex diseases.…”

Section: Introductionmentioning

confidence: 99%